Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 18/20 | 0.35 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.31 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.31 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.31 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.31 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.31 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10011668 | 0.92 | PPARG (0.35) | FFAR1AKR1B1AKR1C4AKR1C3AKR1C2 | |
| SCHEMBL10010677 | 0.92 | PPARG (0.35) | FFAR1AKR1B1AKR1C4AKR1C3AKR1C2 | |
| SCHEMBL10010671 | 0.92 | PPARG (0.35) | FFAR1AKR1B1AKR1C4AKR1C3AKR1C2 | |
| SCHEMBL10011672 | 0.92 | PPARG (0.35) | FFAR1AKR1B1AKR1C4AKR1C3AKR1C2 | |
| SCHEMBL1707830 | 0.89 | FFAR1 (0.34) | FFAR1 | |
| SCHEMBL10009833 | 0.88 | AKR1C3 (0.41) | FFAR1AKR1B10AKR1B1AKR1C4AKR1C3 | |
| SCHEMBL10009839 | 0.88 | AKR1C3 (0.41) | FFAR1AKR1B10AKR1B1AKR1C4AKR1C3 | |
| SCHEMBL1707754 | 0.86 | AKR1B1 (0.31) | AKR1B10AKR1B1AKR1C4AKR1C3AKR1C2 | |
| SCHEMBL10009327 | 0.85 | PPARG (0.36) | FFAR1 | |
| SCHEMBL10009325 | 0.85 | PPARG (0.36) | FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2440541-A1 | NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2012-04-18 | — | — | EP | disclosed |